Targeted therapy for patients with advanced hepatocellular carcinoma usually makes sense and can significantly prolong the survival time as well as improve the quality of life of advanced patients. Advanced liver cancer has lost the chance of surgical resection, and non-surgical treatment based on systemic anti-tumor therapy is preferred. The treatment modalities mainly include: targeted therapy/immunotherapy, TACE, surgery, radiotherapy, chemotherapy, etc. Targeted therapy/immunotherapy: mainly atilizumab combined with bevacizumab, sindilizumab combined with bevacizumab analog, donafenib, lenvatinib, sorafenib and other first-line treatments. Sorafenib is a commonly used targeted therapeutic agent for hepatocellular carcinoma, and its main mechanism is to inhibit neovascularization in hepatocellular carcinoma. The SHARP study confirmed the effectiveness of Sorafenib in treating advanced liver cancer, with a median overall survival of 10.7 months in the Sorafenib treatment group and 7.9 months in the placebo group. Orâ… ental conducted a similar multicenter clinical trial in Asia, with a median overall survival of 6.5 months in Sorafenib and 4.2 months in the placebo group. In conclusion, it is recommended that patients diagnosed with advanced hepatocellular carcinoma should go to regular hospitals for evaluation of their condition, and cooperate with the treatment as prescribed by the doctor to control the progression of the disease and improve the prognosis of the patients. Please strictly follow the doctor’s instructions for drug treatment, and do not use drugs on your own.